Cite
HARVARD Citation
Tombal, B. et al. (2019). Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. Lancet oncology. 20 (4), pp. 556-569. [Online].